Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: A review

Clinical Drug Investigation

Volumn 27, Issue 9, 2007, Pages 591-604

  Frisinghelli, Anna ^a,c   Mafrici, Antonio ^b  

^a Divisione di Cardiologia   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c RHO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; COLESTIPOL; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANGIOGRAPHY; ATHEROSCLEROSIS; B SCAN; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE COURSE; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SMOKING; STATISTICAL SIGNIFICANCE;

ADULT; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; CORONARY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MIDDLE AGED; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 34548091306     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727090-00001     Document Type: Review

References (56)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25): 3143-421
2. Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. BMJ 2000; 320 (7236): 705-8
3. Blumenthal RS. Statins: effective antiatherosclerotic therapy. Am Heart J 2000; 139 (4): 577-83
4. Klotz U. Pharmacological comparison of the statins. Arzneimittelforschung 2003; 53 (9): 605-11
5. Farnier M. The hyperlipidemias: role of various statins [in French]. Presse Med 1999; 28 (36): 2002-10
6. Singh BK, Mehta JL. Management of dyslipidemia in the primary prevention of coronary heart disease. Curr Opin Cardiol 2002; 17 (5): 503-11
7. Gotto Jr AM, Farmer JA. Pleiotropic effects of statins: do they matter? Curr Opin Lipidol 2001; 12 (4): 391-4
8. Rackley CE. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996; 19 (9): 683-9
9. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. Arch Intern Med 1993; 153 (9): 1079-87
10. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: III. Efficacy in modifying lipoproteins and implications for managing patients with moderate hypercholesterolemia. Am J Med 1991; 91 (1B): 18S-24S
11. Swislocki AL, Lin K, Cogburn D, et al. Postmarketing analysis of lovastatin use in the VA Northern California System of Clinics: a retrospective, computer-based study. Am J Manag Care 1997; 3 (10): 1537-45
12. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998; 82 (4B): 3J-10J
13. Rossouw J. Workshop on stabilization and regression of atherosclerosis. Newspaper Cardiol 1991; Aug 1
14. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279 (20): 1615-22
15. Furberg CD, Adams Jr HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994; 90 (4): 1679-87
16. Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991; 151 (1): 43-9
17. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323 (19): 1289-98
18. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119 (10): 969-76
19. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89 (3): 959-68
20. Waters D, Higginson L, Gladstone P, et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation 1995; 92 (9): 2404-10
21. Waters D, Lesperance J, Gladstone P, et al. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis: a Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. CCAIT Study Group. Circulation 1996; 94 (4): 614-21
22. Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 2001; 10 (10): 971-81
23. Gotto Jr AM, Boccuzzi SJ, Cook JR, et al. Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. Am J Cardiol 2000; 86 (11): 1176-81
24. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published erratum appears in N Engl J Med 1997; 337: 356]. N Engl J Med 1997; 336: 973-9
25. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-43
26. Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-42
27. Danesh J, Whincup P, Walker M, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204
28. Ridker PM, Stampfer MJ, Nifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5
29. Ridker PM, Rifai N, Pfeffer M, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999; 100: 230-5
30. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001; 103: 1191-3
31. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344 (26): 1959-65
32. Probstfield JL, Margitic SE, Byington RP, et al. Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study. Am J Cardiol 1995; 76 (9): 47C-53C
33. Bradford RH, Shear CL, Chremos AN, et al. Expanded clinical evaluation of lovastatin (EXCEL) study: design and patient characteristics of a double-blind, placebo-controlled study in patients with moderate hypercholesterolemia. Am J Cardiol 1990; 66 (8): 44B-55B
34. Hodis HN, Mack WJ, LaBree L, et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial. Ann Intern Med 1996; 124 (6): 548-56
35. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90 (1): 42-9
36. Pyorala K, Laakso M, Uusihpa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1987; 3: 463-524
37. Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 1988; 318 (2): 81-6
38. Garg A, Grundy SM. Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin. Am J Cardiol 1988; 62 (15): 44J-9J
39. Dujovne CA, Chremos AN, Pool JL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991; 91 (1B): 25S-30S
40. Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81 (5): 582-7
41. Schectman G, Hiatt J. Dose-response characteristics of cholesterol-lowering drug therapies: implications for treatment. Ann Intern Med 1996; 125 (12): 990-1000
42. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326 (7404): 1423
43. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998; 32 (3): 665-72
44. Zhou Z, Rahme E, Abrahamowicz M, et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ 2005; 172 (9): 1187-94
45. Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28 (1): 26-35
46. Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87 (9): 1074-9
47. Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res 1990; 50: 65-78
48. Laties AM, Shear CL, Lippa EA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results: II. Assessment of the human lens after 48 weeks of treatment with lovastatin. Am J Cardiol 1991; 67 (6): 447-53
49. Chylack Jr LT, Mantell G, Wolfe JK, et al. Lovastatin and the human lens: results of a two year study. The MSDRL Study Group. Optom Vis Sci 1993; 70 (11): 937-43
50. Pedersen TR. Statin trials and goals of cholesterol-lowering therapy after AMI. Am Heart J 1999; 138 (2 Pt 2): S177-82
51. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350 (15): 1495-504
52. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352 (14): 1425-35
53. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291 (9): 1071-80
54. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295 (13): 1556-65
55. Crouse 3rd JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR trial. JAMA 2007; 297 (12): 1344-53
56. Shovman O, Levy Y, Gilburd B, et al. Antiinflammatory and immunomodulatory properties of statins. Immunol Res 2002; 25 (3): 271-85